Teva Pharmaceutical Industries Ltd (TEVA): Capital Expenditures
$501.00M
Year ended 2025-12-31
$551.00M
Trailing 12 months to 2026-06-30
-2.9%
3-year compound annual growth
-2.8%
5-year compound annual growth
-4.2%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $501.00M | +0.6% | 2026-02-03, From 2025-01-01 |
| 2024-12-31 | $498.00M | -5.3% | 2026-02-03, From 2024-01-01 |
| 2023-12-31 | $526.00M | -4.0% | 2026-02-03, From 2023-01-01 |
| 2022-12-31 | $548.00M | -2.5% | 2025-02-05, From 2022-01-01 |
| 2021-12-31 | $562.00M | -2.8% | 2024-02-12, From 2021-01-01 |
| 2020-12-31 | $578.00M | +10.1% | 2023-02-10, From 2020-01-01 |
| 2019-12-31 | $525.00M | -19.4% | 2022-02-09, From 2019-01-01 |
| 2018-12-31 | $651.00M | -25.5% | 2021-02-10, From 2018-01-01 |
| 2017-12-31 | $874.00M | -3.0% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $901.00M | +16.7% | 2019-02-19, From 2016-01-07 |
| 2015-12-31 | $772.00M | -16.9% | 2018-02-12, From 2015-01-01 |
| 2014-12-31 | $929.00M | -9.9% | 2017-02-15, From 2014-01-01 |
| 2013-12-31 | $1.03B | -6.6% | 2016-02-11, From 2013-01-01 |
| 2012-12-31 | $1.10B | +4.8% | 2015-02-09, From 2012-01-01 |
| 2011-12-31 | $1.05B | +48.3% | 2014-02-10, From 2011-01-01 |
| 2010-12-31 | $710.00M | -1.3% | 2013-02-12, From 2010-01-01 |
| 2009-12-31 | $719.00M | +5.6% | 2012-02-17, From 2009-01-01 |
| 2008-12-31 | $681.00M | +25.6% | 2011-02-15, From 2008-01-01 |
| 2007-12-31 | $542.00M | n/a | 2010-02-22, From 2007-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $501.00M | +0.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $898.40M | +18.9% |
| Viatris Inc (VTRS) | 2025-12-31 | $378.80M | +16.2% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $437.60M | +47.0% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $397.00M | +17.8% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $621.00M | -5.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| Organon & Co. (OGN) | 2025-12-31 | $162.00M | -7.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
Compare TEVA, REGN, VTRS, VRTX side by side · Screen every company in Pharmaceutical Preparations ↗